A Quantitative Symptom-Therapy Efficacy Matching Matrix for Precision Treatment Selection in Functional Dyspepsia (ACG 2026) - Aug 29, 2026 - Abstract #P2139; Pres time: Oct 11, 2026; 03:30 PM - 07:00 PM; Location: Exhibit Halls A - D (Level 3); "Quantitative efficacy data were extracted from five RCTs that report on five different drugs - acotiamide, itopride, buspirone, lansoprazole, and nortriptyline . Matrix-guided therapy selection demonstrated superior match scores across all profiles: pure PDS (itopride 0.317, acotiamide 0.231), pure EPS (itopride 0.307, tricyclic antidepressants 0.218, proton pump inhibitors 0.212), and nausea-dominant (itopride 0.403, tricyclic antidepressants 0.264). K-means clustering confirmed Rome IV subtype separation (k=3, silhouette score 0.771). Monte Carlo validation showed model-guided responder rates exceeded empiric care by 21â28% across profiles, with simulation error < 4% versus published RCT benchmarks."
Clinical • Dyspepsia • Musculoskeletal Pain
|
|
Fnu Aakriti MBBS 1; Laiba Manzoor MBBS 2; Iman Khan MBBS 3; Safia Bibi MBBS 4; Dadullah Faiz 5; Prince Kusimw'iragi 6; Abdul Rahim Soroush 7; Emil Vergis Philip MBBS 8; Abdul Basit 9; Denishkumar P. Godhavia MBBS 10; Noorin Riya T S MBBS 11; Rupalakshmi Vijayan MD 12
|